Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New flexible scope aims to make lung lining diagnosis easier and more accurate

NCT ID NCT07114783

Diagnosis Sponsor: China-Japan Friendship Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests a new dual-function semirigid thoracoscope against the standard rigid thoracoscope for diagnosing pleural disease (fluid buildup around the lungs). The new device is designed to be easier to maneuver and potentially less painful while still obtaining large tissue samples. About 92 adults with unexplained pleural effusion will be randomly assigned to one of the two procedures to see which provides a clearer diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dual-function semirigid thoracoscope
What this could lead to
If successful, this new device could offer a more comfortable and easier-to-use tool for diagnosing pleural diseases, potentially matching the accuracy of current methods.
What could go wrong
This is a relatively small trial, and the new device may not prove as effective or safe as the standard rigid thoracoscope in all cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 92 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years; 2. Patients with unilateral pleural effusion of unclear aetiology after less invasive means of diagnosis; 3. Fully informed of the purpose and method of the study, agreed to participate in the study, and signed the informed consent form. Exclusion Criteria: 1. Patients with PaO2/FiO2 \<300; 2. Patients with a tendency for uncontrolled bleeding, unstable cardiovascular status or severe heart failure; 3. Patients with complete pleural symphysis, where it was not possible to create a pneumothorax, were excluded subsequently; 4. Patients with refractory cough; 5. Patients with Eastern Cooperative Oncology Group performance status 4; 6. Patients did not agree to participate in this study; 7. Participation in other studies within three months without withdrawal or termination will affect the observation of this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pleural effusion disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pleural disorder Pleural Effusion

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pleural effusion disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.